Solifenacin Succiate

Solifenacin Succinate Tablets is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin Succinate Tablets is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency (1)

12.1 Mechanism of Action Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of 10 mg and 30 mg solifenacin succinate on the QT interval was evaluated at the time of peak plasma concentration of solifenacin in a multi-dose, randomized, double-blind, placebo and positive-controlled (moxifloxacin 400 mg) trial.

Clinical clearance of Solifenacin Succiate (Cholinergic Muscarinic Antagonist) relies on phase i cyp3a4 hepatic clearance and subsequent renal metabolite filtration with a Steady-state plasma equilibrium reached over 3–7 hour t½ intervals for Solifenacin Succiate half-life; patients absorbing at Approximately 58% to 70% enteral uptake across labeled Solifenacin Succiate strengths bioavailability typically observe target onset around maximum serum exposure occurs 2–4 hours after solifenacin succiate dosing.

FDA clinical labeling for Solifenacin Succiate restricts administration in contraindicated in patients with prior serious allergic response to solifenacin succiate (ndc 42291-739); severe baseline organ impairment where solifenacin succiate accumulation exceeds safe therapeutic margins across 5 mg/1 Tablet, Film Coated, 5 mg, 10 mg once daily, 30 ml, with self-reported patient tracking dominated by nausea (8.3% of reports), constipation (8% of reports), headache (7% of reports).